aTyr Pharma (FRA:471A) Interest Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is aTyr Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. aTyr Pharma's interest expense for the three months ended in Dec. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. aTyr Pharma's Operating Income for the three months ended in Dec. 2024 was € -15.11 Mil. aTyr Pharma's Interest Expense for the three months ended in Dec. 2024 was € 0.00 Mil. GuruFocus does not calculate aTyr Pharma's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

aTyr Pharma Interest Expense Historical Data

The historical data trend for aTyr Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Interest Expense Chart

aTyr Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

aTyr Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

aTyr Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

aTyr Pharma (FRA:471A) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

aTyr Pharma's Interest Expense for the three months ended in Dec. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-15.11 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €11.49 Mil.

aTyr Pharma's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate aTyr Pharma's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. aTyr Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

aTyr Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (FRA:471A) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ATYR:USA

Address

10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121

Website

https://www.atyrpharma.com

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Headlines

No Headlines